Pfizer-BioNTech coronavirus vaccine wins full FDA approval, potentially persuading the hesitant to get a shot
…from the Washington Post
[ Editor’s Note: Hopefully this will bring a badly a needed bump in vaccinations, but it is not expected to do so for individuals concerned about long term effects. The current bump in red state vaccinations is the high infection, hospitalization and death rate states. Local media mortality news seems to be doing the trick.
The main vax boost will come from businesses that did not want to risk getting sued for terminating employees for refusing to get a vaccine still in the experimental approval stage. Expect to see more companies requiring them, which will generate unhappiness with some people.
This could be a lingering problem with people’s lives being disrupted looking for new jobs that can require relocation, kids changing schools…but all preferable to dying of Covid.
For the unlucky ones who get it, to be hospitalized for 10 days and go home is about a $120,000 bill, which for uninsured people is a bankruptcy which would include their home. For those that go into the ICU, then a ventilator, and then die, figure about $400,000.
So for a male Covid fatality, that would be leaving a wife and kids broke, moving in with grandparents or whatever. I am surprised we have not seen any media stories about the families’ finance destruction and the bleak future they have.
Someone will get around to it eventually. We take each day as it comes, which includes one like today with the Alabama anti-vax loons on cross country joyrides threatening death sentences for anyone giving a vaccine… Jim W. Dean ]
First published … August 23, 2021
“As the first FDA-approved covid-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness and manufacturing quality the FDA requires of an approved product,” FDA acting commissioner Janet Woodcock said in a statement.
…“It’s been remarkably fast,” said Holly Fernandez Lynch, a bioethics expert and lawyer at the University of Pennsylvania who said careful handling of the approval was crucial to potentially persuading the “vaccine hesitant” to receive the licensed product. “You can’t have it both ways. You can’t have people saying they won’t get vaccinated until there’s full approval and then say the FDA has to hurry up” and grant that approval.